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843-3 Late Quantitative Angiographic Results Following 
Treatment With a Polymer-Based Paclitaxel-Eluting 
Stent Compared With a Bare Metal Stent in Patients 
With De Novo Coronary Disease: The TAXUS-IV 
Angiographic Results
Jeffrey J. Popma, Stephen G. Ellis, David Cox, James Hermiller, Jr., Charles 
O'Shaughnessy, James Tift Mann, Mary E. Russell, Gregg Stone, The TAXUS IV 
Investigators, Cleveland Clinic Foundation, Cleveland, OH, Brigham and Women’s 
Hospital, Boston, MA
Background: A reduction in restenosis has been shown with paclitaxel-eluting stents in
patients with focal stenoses in native coronary arteries, but the benefit of these stents
has not been shown in more complex lesion subsets.
Methods: The TAXUS-IV study randomized 1,326 patients with complex coronary steno-
sis to single vessel treatment with the paclitaxel-eluting or bare metal Express™ stent. Of
these, 732 patients were assigned to 9 month angiographic follow-up and late repeat
angiography was performed in 559 (76.4%) of these patients. Quantitative angiographic
analysis (CMS, Medis) was performed at baseline, after the stent procedure and at late
angiographic follow-up. Analysis of the lumen changes within the stent (IS), its 5-mm
proximal and distal edges, and within the analysis segment (AS; in-stent plus 5 mm prox-
imal and distal) was performed.
Results: In patients assigned to angiographic restudy, diabetes was present in 25.8% of
patients, the reference vessel diameter was 2.8 mm, and the average lesion length was
14.4 mm. At late angiographic follow-up, there were significant reductions in all parame-
ters of late lumen re-narrowing with the use of the paclitaxel-eluting stent: 
Conclusions: We conclude that restenosis within the stent, within its 5-mm proximal and
distal edges, and within the analysis segment is significantly reduced with the use of the
paclitaxel-eluting stent.
2:45 p.m.
843-4 Reduction in Late Loss and Restenosis in Patients With 
Small Vessels Treated With the Slow Rate-Release, 
Polymer-Based Paclitaxel-Eluting Stent: Results From 
TAXUS-IV
Gregg W. Stone, Stephen G. Ellis, Charles O'Shaughnessy, James Tift Mann, Mark 
Turco, Albert Raizner, Louis Cannon, Michael Kutcher, Paul Gurbel, S. Chiu Wong, Mary 
E. Russell, Jeffrey J. Popma, The TAXUS IV Investigators, Cardiovascular Research 
Foundation, New York, NY, Brigham and Women's Hospital, Boston, MA
Background. The relative efficacy of the polymer based paclitaxel slow release eluting
TAXUS stent in small vessels with de novo lesions is unknown.
Methods. In the TAXUS-IV trial, 1,314 patients with de novo lesions ranging from 2.5 –
3.75 mm in diameter and 10-28 mm in length were randomized to treatment with the slow
rate-release, polymer-based paclitaxel-eluting TAXUS stent (n=662) vs. an identical
appearing uncoated EXPRESS stent (n=552).
Results. Of 1381 implanted stents, 424 (31%) were 3.5 mm in diameter, 669 (48%) were
3.0 mm diameter, and 288 (21%) were 2.5 mm in diameter. For the entire study popula-
tion, the TAXUS stent reduced the 9-month TLR and RR from 11.3% with BMS to 3.0%,
and from 26.6% to 7.9% respectively (both P<0.0001). As seen in the table, both TLR
and RRs progressively rose with decreasing stent size among patients receiving BMS. In
contrast, TLR and RRs were independent of stent size with the TAXUS stent. Among
BMS pts, absolute LL was independent of stent size, whereas with TAXUS, LL was signif-
icantly less in smaller stents. 
Conclusions. The paclitaxel-eluting TAXUS stent markedly reduces restenosis, indepen-
dent of vessel size, with reduced late loss and the greatest relative efficacy seen in the
smallest vessels.
3:00 p.m.
843-5 Drug-Eluting Stents for the Treatment of Bifurcated 
Coronary Lesions: A Randomized Comparison of 
Simple Versus Complex-Strategy Approach
Manuel Pan, Alfonso Medina, José Suárez de Lezo, Antonio Delgado, Miguel Romero, 
José Segura, Enrique Hernández, Djordje Pavlovic, Juan Herrador, Isabel Ureña, 
Federico Segura, Reina Sofía Hospital, Córdoba, Spain, Dr. Negrín Hospital, Las Palmas 
de Gran Canaria, Spain
Background: Rapamycin-eluting stents (RES) have shown to reduce restenosis in many
types of lesions. However, to date, the full reconstruction with RES of the entire bifurca-
tion has not been proven to improve the results of a simple strategy. Methods: To com-
pare both strategies we carried out a randomized study in 91 patients with true coronary
bifurcation lesions. All patients received a RES at the main vessel, covering the side
branch (SD). Patients from group A (n=47) were assigned to balloon dilation of the
involved SD (simple strategy); 44 patients (group B) were randomized to receive a sec-
ond stent at the SD origin (complex strategy). There were no differences between groups
regarding baseline clinical and angiographic data. One patient from group A crossed-
over to complex strategy due to a poor immediate result, whereas it was impossible to
implant a stent at the ostium of the SD in 4 patients from group B, so the intervention was
limited to balloon dilation. Results: The table summarizes the immediate and follow-up
results on an intention to treat basis. Six-month angiographic reevaluation was obtained
in 67 patients. Restenosis of the main vessel was observed in one patient from group A
(3%) and in 2 from group B (6%). Restenosis of the SD appeared in 2 patients from
group A (6%) and in 4 from group B (13%). Conclusions: Both strategies are effective,
without any differences in terms of clinical outcome. Elective SD stenting seems to pro-
vide no advantages over the simpler stent jail followed by SD balloon dilation. . 
3:15 p.m.
843-6 Three-Year Follow-Up of the RAVEL Study: A 
Randomized Study With the Sirolimus-Eluting Bx 
VELOCITY™ Stent in the Treatment of Patients With De 
Novo Native Coronary Artery Lesions
Marie-Claude Morice, Patrick Serruys, Costantino Costantini, Egon Wuelfert, William 
Wijns, Jean Fajadet, Antonio Colombo, Giulio Guagliumi, Ferenc Molnar, Ernesto Ban 
Hayashi, J. Eduardo Sousa, Marco Perin, The RAVEL Trial Investigators, Institut 
Cardiovasculaire Paris Sud, Massy, France
Background: Sirolimus, a macrocyclic antibiotic and immunosuppressant, causes late
G1 cell cycle arrest. A pilot study using Sirolimus-eluting stents to treat coronary artery
lesions demonstrated almost no neointimal hyperplasia at 12 months. Results from this
study were used to design RAVEL, a multicenter, double blind, two-arm, randomized
study assessing safety and effectiveness of the Sirolimus-Eluting BX VELOCITY™ stent
versus the uncoated Bx VELOCITY™ stent (18 mm).
Methods: The primary endpoint was angiographic late loss at 6 months. The secondary
endpoints were major adverse cardiac events, target vessel revascularization (TVR), tar-
get lesion revascularization (TLR) and restenosis rate. Inclusion criteria: stable or unsta-
ble angina, single treatment-de novo lesions < 18mm long, 2.5-3.5 mm diameter.
Clopidogrel or Ticlodipine was continued for up to 8 weeks following a loading dose.
Results: From August 2000-December 2000, 238 patients were enrolled at 19 sites in
Quantative Angiographic Analysis
Variable (Number of Lesions) EES (N=22) MS (N=43) P-value
Reference Diameter, mm 2.91±0.33 2.97±0.54 0.6
Final MLD, mm 2.88±0.29 2.87±0.42 0.9
Acute Gain, mm 1.83±0.52 1.83±0.42 1.0
FU Stent MLD, mm 2.74±0.28 2.02±0.74 <0.0001
FU Prox Stent Edge MLD, mm 2.65±0.66 2.66±0.64 1.0
FU Distal Stent Edge MLD, mm 2.43±0.47 2.36±0.53 0.6
Stent Late Loss, mm 0.12±0.28 0.85±0.58 <0.0001
Stent Restenosis, % 0.0% 19.4% 0.04
Segment Restenosis, % 4.8% 30.6% 0.04
Target Vessel Revascularization, % 0.0% 7.5% 0.5
MACE, % 4.8% 17.5% 0.2
Follow-up QCA Control Stent 
(N=357)
TAXUS Stent 
(N=375)
P value
MLD, IS/AS 1.75 / 1.68 2.26 / 2.03 < 0.001/<0.001
Edge, Proximal/Distal 2.51/2.25 2.58/2.34 0.20/0.04
% Stenosis, IS/AS 37.2 / 39.8 17.4 / 26.3 <0.001/ < 0.001
Late Loss, IS/AS 0.92 / 0.61 0.39 / 0.23 < 0.001 / < 0.001
Loss Index, IS/AS 0.56 / 0.48 0.23 / 0.38 < 0.001 / < 0.001
Binary Restenosis, IS/AS 24.4/ 26.6 5.5 / 7.9 < 0.001 / < 0.001
9 month rates by stent diameter Control TAXUS P value
TLR – 2.5 mm 18.0% 3.1% 0.0001
TLR – 3.0 mm 11.5% 3.7% 0.0002
TLR - 3.5 mm 7.3% 1.0% 0.002
RR – 2.5 mm 40.8% 8.8% 0.0002
RR – 3.0 mm 31.2% 9.1% <0.0001
RR – 3.5 mm 12.9% 5.5% 0.13
LL – 2.5 mm 0.65 mm 0.17 mm <0.0001
LL – 3.0 mm 0.61 mm 0.22 mm <0.0001
LL – 3.5 mm 0.60 mm 0.28 mm <0.0001
Immediate and follow-up results
Non-Q myocardial
infarction
Death Target lesion
revascularization
Total major cardiac
events at 6 months
Group A (n=47) 2 (4%) 0 1 (2%) 3 (6%)
Group B (n=44) 0 1(2%) 2 (5%) 3 (7%)
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Europe and South America. Baseline demographics and lesion characteristics were
evenly distributed. No acute, subacute or late thrombosis occurred. The two-years results
are shown below 
Conclusion: The QCA data demonstrate virtually no neointimal in-stent proliferation and
very little TLR and TVR within the Sirolimus group, and with event-free survival of 90% at
two years. Three-year clinical follow-up data will be presented.
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1155-77 Clinical, Angiographic, and Intravascular Ultrasound 
Comparisons Between Patients With Early Versus Late 
Saphenous Vein Graft Failure
Daniel Arthur Canos, Gary S. Mintz, Jose R. Cordero, Esteban Escolar, Jun-Ichi Kotani, 
Natalie Gevorkian, Augusto D. Pichard, Lowell F. Satler, Kenneth M. Kent, Neil J. 
Weissman, Medstar Research Institute, Washington, DC
Background: Up to 20% of saphenous vein grafts (SVG) fail in the 1st yr. The etiology of
early failure is not well understood. Methods: We used coronary angiography and intra-
vascular ultrasound (IVUS) to analyze 100 pts (121 lesions) with early (<1 yr) SVG failure
and 200 pts (289 lesions) with late (>1yr) SVG failure. IVUS assessment included refer-
ence and lesion SVG, lumen, and plaque areas; plaque burden (SVG/plaque area);
remodeling (lesion/reference SVG area); and morphology.
Results: Risk factors were identical in both groups: smoking (44%), diabetes (36%),
hypercholesterolemia (70%), and hypertension (63% early vs 72% late, p = 0.14). Early
failure pts had more anginal rest pain (34.3% vs.19.8%). Comparing early to late failure,
lesion location was proximal in 62% vs 42% (ostial in 37% vs 18%), mid-segment in 13%
vs 29%, distal in 13% vs 20%, and distal anastomosis in 13% vs 5%. Lesion length was
similar (9.6 vs 9.27 mm, p= 0.7). The early failure group had smaller references (IVUS
and angio: 2.74± 0.86 vs 3.26± 0.83 mm, p< 0.01) and little remodeling at the lesion site.
Conversely, late failure lesions had significantly less reference segment plaque burden,
but more mobile plaque elements (21.4% vs 0%, p= 0.01) and calcific plaque (17.9 % vs.
0%, p= 0.02).
Conclusion: Early SVG failure occurs more often at the ostium. Grafts failing <1yr have
more reference segment plaque and less lesion site remodeling suggesting a more
aggressive disease process with intrinsic graft fibrosis. 
1155-78 Implications and Prevention of Large Periprocedural 
Myocardial Infarction After Percutaneous Intervention 
of Diseased Saphenous Vein Grafts and Thrombotic 
Native Coronary Lesions
Zoran Lasic, Roxana Mehran, Eugenia Nikolsky, Manuela Negoita, Ricardo Costa, David 
A. Cox, Joseph Babb, Dean Nukta, Luc Bilodeau, Louis Cannon, Thomas D. Stuckey, 
James Hermiller, Alexandra Lansky, Martin B. Leon, Gregg W. Stone, Lenox Hill Hospital, 
New York City, NY
Background: Peri-procedural myonecrosis after percutaneous coronary intervention
(PCI) is especially common after intervention in saphenous vein grafts (SVG) and throm-
botic lesions, and is strongly associated with worse short and long-term outcomes, espe-
cially when the CPK-MB is >8x normal or Q-wave MI develops. Whether thrombectomy
can decrease the incidence of large peri-procedural myocardial infarctions and improve
outcomes in these high risk situations is unknown.
Methods: We analyzed the effectiveness of thrombectomy with the ev3 X-SIZER in pre-
venting large peri-procedural MIs (Q-wave or CK-MB >8x nl) in the multicenter prospec-
tive X-TRACT trial, in which 797 pts undergoing PCI of diseased SVGs and thrombus
containing native coronary arteries were randomized to thrombectomy vs. control prior to
stenting.
Results: Baseline clinical and demographic data were similar in both groups. Definite
thrombus was present in 191 (47.8%) X-SIZER patients and 164 (41.3%) of control
patients (p<0.07). A total of 60 patients (7.5%) developed a large MI within 30-days after
PCI, including 22 (2.7%) in X-SIZER group and 38 (4.7%) in control group, p<0.03. Large
MI within 30-days after PCI occurred in 10.1% of pts with definite thrombus vs. 5.4% of
pts without definite thrombus (p<0.01). Among pts with thrombus, X-SIZER use
decreased the occurrence of large MI from 14% to 6.8%, p<0.03. The 30-day rate of
repeat target vessel revascularization was increased in pts with vs. without large MI
(8.3% vs. 1.1%, p=0.001). Six-month mortality occurred in 5.0% of patients with CK-MB
>8x normal, compared to 2.4% of pts without CPK-MB >8x normal (p=0.193).
Conclusion: Large peri-procedural myocardial infarctions after intervention in diseased
SVGs and thrombus containing native coronary arteries is associated with an increased
need for early target revascularization, and a trend for increased late mortality. Throm-
bectomy with the X-SIZER prior to stent implantation in these high risk lesions reduces
the occurrence of large peri-procedural myocardial infarctions. Larger studies are
required to demonstrate whether this directly results in a survival advantage with throm-
bectomy.
1155-79 Drug-Eluting Balloon: A New Technique to Deliver 
Paclitaxel to the Angioplasty Site
Kai Hogrefe, Kamal Chitkara, Anthony H. Gershlick, University of Leicester, Leicester, 
United Kingdom
Background:
Paclitaxel, which stabilizes microtubules and renders the affected cell incapable of prolif-
eration and migration, has been shown to reduce neointimal formation. Paclitaxel-loaded
stents have been successfully used in the clinical setting to deliver this very potent agent
to the vessel wall. There are, however, situations such as in- or persistent restenosis or
small vessel angioplasty when a drug eluting stent might not be ideal because of the
thrombosis risk or when their use is inappropriate (edge residual stenosis). In this exper-
iment we loaded paclitaxel onto conventional angioplasty balloon and delivered it to
human arterial wall ex vivo.
Methods:
Whole angioplasty balloons were inflated and then loaded with paclitaxel by immersing
(for 1 hour) into paclitaxel solution (10 mg/ml and 20 mg/ml) spiked with radiolabelled-
paclitaxel. After air-drying, the balloons were placed in scintillation fluid and beta-
counted. Elution of loaded paclitaxel was measured in buffer and blood for up to 10 min.
Paclitaxel loaded balloons were placed inside fresh internal mammary arteries (IMA)
segment, incubated at 37°C and were inflated at 8 atmospheric pressure for 1 and 10
minutes. Intramural deposition was measured after flushing the vessel segment with 5
mls of blood.
Results:
Paclitaxel was loaded successfully onto conventional angioplasty balloon of various
sizes. Corrected for balloon surface area, we achieved paclitaxel loading of 0.22 µg/mm²
after immersion in 10mg/ml paclitaxel solution and 0.37 µg/mm² in 20 mg/ml (p=0.005).
There was little paclitaxel elution in blood and in buffer in the first 10 min (6.2% and 9.7%
respectively). Further, 34.8% paclitaxel was deposited in the artery wall after 1 minute
and 36.7% after 10 minute balloon inflation.
Conclusion:
Paclitaxel can be successfully loaded onto an angioplasty balloon. There was minimal
loss of paclitaxel into blood and up to 34.8% delivery efficiency into internal mammary
artery after 1 minute balloon inflation. Further studies with this novel drug eluting balloon
(DEB) are ongoing to evaluate its effect on smooth muscle cell proliferation in vitro and
restenosis in vivo. Restenosis after balloon angioplasty alone may be reduced.
1155-80 Morbidity and Mortality Associated With Retroperitoneal 
Bleeding Following Percutaneous Coronary 
Intervention With Femoral Artery Access
Charles L. Laham, Mayo Clinic, Rochester, MN
Background: Little is known of the clinical sequelae of retroperitoneal bleeding (RPB) fol-
lowing a femoral access percutaneous coronary intervention (PCI).
Methods and Results: We analyzed the Mayo PCI database and identified 55 patients
(pts) with RPB between 12/01/93 and 6/30/02. We matched 4 pts (controls) without RPB
(total n=220) for each RPB pt based on gender, age within 5 years and PCI within 1 year.
Adverse events in-hospital and at 6 months were analyzed. Among RPB pts, PCI was
Sirolimus Control P-value
Reference diameter (mm) 2.60 2.64 NS
MLD Post-procedure (mm) 2.43 2.41 NS
MLD Follow-up (mm) – 6 month 2.42 1.64 .0001
Late loss (mm) 0.01 0.80 .0001
Restenosis rate (%) 0.0 26.1 .0001
TLR-free – 2 years 97.4 86.2 .0001
TVR-free – 2 years 96.6 83.6 .0001
TVF-free – 2 years 94.1 78.7 .0001
MACE-free – 2 years 90.0 80.5 .0001
IVUS
Characteristics
Early Failure (<1yr) Late Failure (>1yr) p
Distal SVG Area mm2 14.2 ± 7.9 14.6 ± 7.9 0.84
Lumen Area mm2 6.8 ± 5.2 9.9 ± 4.9 0.03
Plaque Burden % 52 ± 17 34 ± 12 <0.01
Proximal SVG Area mm2 14.0 ± 9.5 18.8 ± 7.2 0.08
Lumen Area mm2 6.8 ± 7.9 11.4 ± 4.5 0.02
Plaque Burden 54 ± 19 38 ± 12 0.02
Lesion SVG Area mm2 13.7 ± 7.3 16.8 ± 4.8 0.07
Lumen Area mm2 2.1 ± 1.2 5.0 ± 3.5 < 0.01
Remodeling 0.97 ± 0.23 1.07 ± 0.21 0.09
